Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner

Archives of Dermatological Research

Volumn 290, Issue 9, 1998, Pages 501-507

  Hultsch, T ^a   Muller K D ^a   Meingassner, J G ^b   Grassberger, M ^b   Schopf, R E ^a   Knop, J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b NOVARTIS RESEARCH INSTITUTE   (Austria)

Author keywords

Ascomycin; Inflammation; Mast cells; Pharmacology; SDZ ASM 981

Indexed keywords

ASCOMYCIN; CALCINEURIN; CYCLOPHILIN; CYCLOPHILIN A; CYTOKINE; IMMUNOPHILIN; PIMECROLIMUS; RAPAMYCIN; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INHIBITION; EXOCYTOSIS; GENETIC TRANSCRIPTION; INFLAMMATION; LEUKEMIA CELL LINE; MAST CELL; MAST CELL LEUKEMIA; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RAT;

AMINO ACID ISOMERASES; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-N-ACETYLHEXOSAMINIDASE; CYTOKINES; CYTOPLASMIC GRANULES; IMMUNOPHILINS; MAST CELLS; PEPTIDYLPROLYL ISOMERASE; RECEPTORS, IGE; SEROTONIN; SIROLIMUS; TACROLIMUS; TACROLIMUS BINDING PROTEINS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031695577     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004030050343     Document Type: Article

References (49)

1. Galli SJ, Wershil BK (1996) The two faces of the mast cell. Nature 381:21-22
2. Echtenacher B, Mannel DN, Hultner L (1996) Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77
3. Gordon JR, Burd PR, Galli SJ (1990) Mast cells as a source of multifunctional cytokines. Immunol Today 11.458-464
4. Galli SJ, Wershil BK (1995) Mouse mast cell cytokine production: role in cutaneous inflammatory and immunological responses. Exp Dermatol 4:240-249
5. Longley J, Duffy TP, Kohn S (1995) The mast cell and mast cell disease. J Am Acad Dermatol 32:545-561
6. Rappersherger K, Meingassner JG, Fialla R, Fodinger D, Sterniczky B, Rauch S, Putz E, Stütz A, Wolff K (1996) Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 106:701-710
7. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stütz A (1997) A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 137;568-576
8. Mrowietz U, Brautigam M, Gräber M, Thurston M, Weidinger G, Christophers E (1997) Topical treatment with the anti-inflammatory macrolactam SDZ ASM 981 suppresses plaque-type psoriasis. Australas J Dermatol 38 [Suppl 2]:44-45 (Abstract)
9. Queille-Roussel C, Gräber M, Wagenaar A, Thurston M, Lachapelle JM, Decroix J, De Cuyper C, Ortonne JP (1997) Topical treatment with the anti-inflammatory macrolactam SDZ ASM 981 inhibits established nickel contact dermatitis. Australas J Dermatol 38 [Suppl 2]:55 (Abstract)
10. Van Leent EJM, Gräber M, Thurston M (1997) Topical treatment with the macrolactam SDZ ASM 981 is effective in atopic dermatitis. Australas J Dermatol 38 [Suppl 2]:234 (Abstract)
11. Xu RX, Meadows RP, Fesik SW (1993) Heteronuclear 3D NMR studies of water bound to an FK506 binding protein/immunosuppressant complex. Biochemistry 32:2473-2480
12. Meadows RP, Nettesheim DG, Xu RX, Olejniczak ET, Petros AM, Holzman TF, Severin J, Gubbins E, Smith H, Fesik SW (1993) Three-dimensional structure of the FK506 binding protein/ascomycin complex in solution by heteronuclear three- and four-dimensional NMR. Biochemistry 32:754-765
13. Petros AM, Gemmecker G, Neri P, Olejniczak ET, Nettesheim D, Xu RX, Gubbins EG, Smith H, Fesik SW (1992) NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. J Med Chem 35:2467-2473
14. Hultsch T, Albers MW, Schreiber SL, Hohman RJ (1991) Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. Proc Natl Acad Sci USA 88:6229-6233
15. De Paulis A, Cirillo R, Ciccarelli A, Condorelli M, Marone G (1991) FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. J Immunol 146:2374-2381
16. De Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G (1992) Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 99:723-728
17. Schreiber SL (1991) Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251: 283-287
18. Schreiber SL (1992) Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell 70:365-368
19. Liu J (1993) FK 506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 14: 290-295
20. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815
21. Fruman DA, Bierer BE, Benies JE, Burakoff SJ, Austen KF, Katz HR (1995) The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol 154:1846-1851
22. Hutchinson LE, McCloskey MA (1995) Fc epsilon RI-mediated induction of nuclear factor of activated T-cells. J Biol Chem 270:16333-16338
23. Fischer G, Bang H, Mech C (1984) Nachweis einer Enzymkatalyse für die cis-trans-Isomerisierung der Peptidbindung in prolinhaltigen Peptiden. Biomed Biochim Acta 43:1101-1111
24. Hohman RJ, Hultsch T (1990) Cyclosporin A: new insights for cell biologists and biochemists. New Biologist 2:663-672
25. Hultsch T, Rodriguez JL, Kaliner MA, Hohman RJ (1990) Cyclosporin A inhibits degranulation of rat basophilic leukemia cells and human basophils. Inhibition of mediator release without affecting PI hydrolysis or Ca++ fluxes. J Immunol 144(7): 2659-2664
26. Maeyama K, Hohman RJ, Metzger H, Beaven MA (1986) Quantitative relationships between aggregation of IgE receptors, generation of intracellular signals, and histamine secretion in rat basophilic leukemia (2H3) cells. J Biol Chem 261:2583-2592
27. Bashkin P, Razin E, Eldor A, Vlodavsky I (1990) Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix. Blood 75:2204-2212
28. Espevik T, Nissen Meyer J (1986) A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95: 99-105
29. Fischer G (1989) Slow conformational changes and their enzymology. Novo Acta Leopoldina 61 (269):35-53
30. Fischer G, Wittmann-Liebold B, Kiefhaber T, Schmid FX, Lang K (1989) Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337:476-478
31. De Paulis A, Cirillo R, Ciccarelli A, Crescenzo G de, Oriente A, Marone G (1991) Characterization of the anti-inflammatory effect of FK-506 on human mast cells. J Immunol 147:4278-4285
32. Bierer BE, Somers PK, Wandless TJ, Burakoff SJ, Schreiber SL (1990) Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 250:556-559
33. Baumgartner RA, Deramo VA, Beaven MA (1996) Constitutive and inducible mechanisms for synthesis and release of cytokines in immune cell lines. J Immunol 157:4087-4093
34. Baumgartner RA, Yamada K, Deramo VA, Beaven MA (1994) Secretion of TNF from a rat mast cell line is a brefeldin A-sensitive and a calcium/protein kinase C-regulated process. J Immunol 153:2609-2617
35. Ohno I, Tanno Y, Yamauchi K, Ida S, Takishim T (1988) The production of tumor necrosis factor-alpha by rat basophilic leukemia cells with triggering IgE receptor. Tohoku J Exp Med 156:209-210
36. Hide I, Toriu N, Nuibe T, Inoue A, Hide M, Yamamoto S, Nakata Y (1997) Suppression of TNF-alpha secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation. J Immunol 159:2932-2940
37. Flanagan WM, CorthÎsy B, Bram RJ, Crabtree GR (1991) Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352:803-807
38. Hultsch T, Brand P, Lohman S, Saloga J, Kincaid RL, Knop J (1998) Direct evidence that FK506-inhibition of FceRI-mediated exocytosis from mast cells involves calcineurin. Arch Dermatol Res 290:258-263
39. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756-758
40. Sabatini DM, Erdjument Bromage H, Lui M, Tempst P, Snyder SH (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35-43
41. De Paulis A, Cirillo R, Ciccarelli A, Colombo M, Marone G (1991) Antiinflammatory effect of FK 506 on human basophils. Transplant Proc 23:2905-2906
42. Pedersen C, Permin H, Stahl Skov P, Norn S, Svenson M, Mos bech H, Bendtzen K (1985) Inhibitory effect of cyclosporin A on histamine release from human leukocytes and rat mast cells. Allergy 40:103-107
43. Marone G, Triggiani M, Cirillo R, Giacummo A, Siri L, Condorelli M (1988) Cyclosporin A inhibits the release of histamine and peptide leukotriene C4 from human lung mast cells. La Ricerca Clin Lab 18:53-57
44. Triggiani M, Cirillo R, Lichtenstein LM, Marone G (1989) Inhibition of histamine and prostaglandin D2 release from human lung mast cells by cyclosporin A. Int Arch Allergy Appl Immunol 88:253-255
45. Casolaro V, Spadaro G, Patella V, Marone G (1993) In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils. J Immunol 151:5563-5573
46. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S (1992) Inhibition of contact allergy reactions by topical FK506. Lancet 340:556-556
47. Lauerma AI, Stein BD, Homey B, Lee CH, Bloom E, Maibach HI (1994) Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch Dermatol Res 286: 337-340
48. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pederson K, Daniel F, Finzi A, Reitamo S (1997) A short term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 337:816-821
49. Meingassner JG, Stütz A (1992) Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 98:851-855